Omega CRO omega-cro.com.tr
Rare disease · Patient recruitment

Your rare disease trial is behind on enrolment. Turkey has the patients.

We add activated Turkish sites and genetically confirmed patients to ongoing Phase 2–3 studies, without changing your protocol.

Book a 20-minute feasibility call Reply within one business day.

The problem

Your existing sites have already screened the patients they know.

Adding a new country usually means 9–12 months of start-up before the first patient.

Why Turkey

High prevalence of recessive disease.

About 1 in 4 marriages in Turkey is consanguineous, so autosomal recessive conditions are far more common than in Western Europe. 1

Patients are findable.

Rare disease care is concentrated in a small number of university and city hospitals, so named cohorts are reachable.

Genetic confirmation in-house.

Our sister company Omega Genetik runs the diagnostic panel, so eligibility is confirmed before the patient reaches your site.

What we do

  • Country feasibility with named sites and patient counts
  • TİTCK and ethics submissions, contracts and site activation
  • Pre-screening through patient associations and genetic testing
  • Site monitoring, data management and pharmacovigilance in Turkey
  • Rescue model: we join as an extra country under your lead CRO

How it works

  1. 2 weeks

    Feasibility

    You send the synopsis; we return sites, patient numbers and a timeline.

  2. Start-up

    Submissions, contracts, site training.

  3. Enrolment

    Pre-screened patients are referred to activated sites.

  4. Delivery

    Data flows into your EDC; monitoring follows your plan.

Proof

  • Founded 1997
  • 1,226 projects delivered
  • ICH-GCP
  • ISO 9001
  • ISO/IEC 27001
  • FDA 21 CFR Part 11 systems

Tell us your indication. We will tell you how many patients we can find.

Reply within one business day.

Book your feasibility call

Your details are used only to respond to your enquiry, under our privacy policy.

Sources

  1. 1. Koç İ., "The causal relationship between consanguineous marriages and infant mortality in Turkey", Journal of Biosocial Science 49(6), 2017 — Turkey Demographic and Health Survey data: 24% of marriages consanguineous. https://www.cambridge.org/core/journals/journal-of-biosocial-science/article/causal-relationship-between-consanguineous-marriages-and-infant-mortality-in-turkey/8833E2FA100581DB70C4CDF4D9BA3D16